Compass Pathways reports a post-hoc analysis saying COMP360 trial monitoring and support are distinct from psychotherapy in psilocybin treatment research

COMP360 psilocybin treatment research is presented as separating trial monitoring and psychological support from psychotherapy. Compass Pathways says a post-hoc analysis found that the support model used in COMP360 studies was designed to ensure participant safety, session consistency, and protocol adherence rather than to deliver a therapeutic psychotherapy intervention. The distinction matters for how psilocybin-assisted treatment is interpreted in clinical development and regulation. If monitoring and support are not equivalent to psychotherapy, treatment effects may be attributed more specifically to the investigational drug and the structured trial framework rather than to a full psychotherapeutic program. The claim also speaks to training, scalability, and commercialization. A support model framed around safety and standardized care could require different staffing, oversight, and reimbursement assumptions than models that depend on intensive psychotherapy before, during, and after dosing.